References
- Ritter J, Creutzig U, Schellong G. Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87. AML-BFM-Group. Leukemia. 1992;6: 59–62.
- Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996;87:4979–4989.
- Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working party. Br J Haematol. 1998;101:130–140.
- Bonetti F, Zecca M, Pession A, et al. Total-body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. The Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplantation Group. J Gun Oncol. 1999;17:3729–3735.
- Tiedeman K, Waters KD, Tauro GP, et al. Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission. Blood. 1993;82:3730–3738.
- Afify Z, Shaw PJ, Clavano-Harding A, Cowell CT. Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide. Bone Marrow Transplant. 2000;25:1087–1092.